I spent the day (4/27/10) multitasking – writing and watching the hearings re Goldman for their historical significance. I felt motivated to think about my own policies and disclosure (which are substantial). The above-captioned title provokes action – that I need (also believe) to update our definitions! It is better that I practice than define! Having made that statement, the company specific and regulatory disclosure and legal disclaimers are all readily defined in our website.
NeoStem, Inc. (NBS) announced a collaboration with ImmuneRegen Biosciences, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS). NeoStem will investigate whether Homspera, ImmuneRegen’s lead product, will enhance stem cell activity when used in combination with NBS’s VSEL technology.
BTIM Announced (4/29/10) that it has agreed to acquire the Singapore-based company ES Cell International Pte Ltd (ESI) to accelerate BioTime’s development of human stem cell-based therapeutics. The acquisition is expected to close next week.
The National Institutes of Health (4/28/10) announced that 13 additional lines of human embryonic stem cells are eligible for federal funding. The NIH’s approval of the lines should alleviate mounting concerns among some supporters of stem cell research that the Obama administration was hindering the work. The federal approval includes 9 lines that had never before been eligible for federal funding and 4 ong-used lines derived by researchers at the University of Wisconsin, known as H7, H9, H13 and H14. H9 is the most widely used.
Experimental Telomerase Inhibitor, Imetelstat, Starting Stage II Multiple Myeloma Trials, Geron (GERN)
- 2 randomized trials in non-small cell lung cancer and breast cancer,
- 2 single arm trials in multiple myeloma and essential thrombocythemia.
Cellular Dynamics International (CDI), already a manufacturer of human heart cells, has closed on a $40.6 M Series B private equity round. This financing enables increasing production capacity for its iCell(TM) Cardiomyocytes, human heart cells derived from induced pluripotent stem cells (iPSCs), and to launch additional human tissue cell products for biomedical, pharmaceutical drug development and safety research.
StemCells (STEM) is seeking permission from the FDA to start a 2nd clinical trial of its proprietary HuCNS-SC human neural stem cells in neuronal ceroid lipofuscinosis (NCL), which is also often referred to as Batten disease.
PSTI announced (4/26/10) interim results from its Phase I clinical trial utilizing its placenta-derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). A total of 21 patients, representing 77% of the cohorts required to complete the Phase I dose-escalating studies in the US and Germany have been dosed with PLX-PAD. This includes 15 patients dosed in Germany, representing the complete patient enrollment in that country.
CLI is the term used for patients with chronic ischemic rest pain, ulcers, or gangrene that is attributable to inadequate blood flow or arterial occlusive disease. CLI is typically identified as the end stage of peripheral arterial disease. CLI is the most severe form of PAD, and is typically the end stage of the disease.